RYTHM, Inc.RYMEarnings & Financial Report
RYTHM, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for rare genetic endocrine and metabolic disorders with high unmet medical needs. It primarily operates in the U.S. market, targeting pediatric and adult patient segments that lack standard effective treatment options.
RYM Q4 FY2025 Key Financial Metrics
Revenue
$10.7M
Gross Profit
$8.0M
Operating Profit
$-12.9M
Net Profit
$-13.6M
Gross Margin
75.5%
Operating Margin
-121.5%
Net Margin
-127.6%
YoY Growth
242.0%
EPS
$-6.78
RYTHM, Inc. Q4 FY2025 Financial Summary
RYTHM, Inc. reported revenue of $10.7M (up 242.0% YoY) for Q4 FY2025, with a net profit of $-13.6M (up 44.1% YoY) (-127.6% margin). Cost of goods sold was $2.6M, operating expenses totaled $21.0M.
Key Financial Metrics
| Total Revenue | $10.7M |
|---|---|
| Net Profit | $-13.6M |
| Gross Margin | 75.5% |
| Operating Margin | -121.5% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
RYTHM, Inc. Q4 FY2025 revenue of $10.7M breaks down across 2 segments, led by Nonlicensing Revenue at $9.5M (89.2% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Nonlicensing Revenue | $9.5M | 89.2% |
| Cultivation Business Discontinued Operations | $1.2M | 11.1% |
RYTHM, Inc. Revenue by Segment — Quarterly Trend
RYTHM, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Nonlicensing Revenue and Cultivation Business Discontinued Operations) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Nonlicensing Revenue | $9.5M | $3.5M | — | — |
| Cultivation Business Discontinued Operations | $1.2M | — | — | — |
RYTHM, Inc. Annual Revenue by Year
RYTHM, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $17.3M).
RYTHM, Inc. Quarterly Revenue & Net Profit History
RYTHM, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $10.7M | +242.0% | $-13.6M | -127.6% |
| Q3 FY2025 | $4.0M | +109.0% | $-10.7M | -263.8% |
| Q2 FY2025 | $2.0M | -31.8% | $-7.4M | -360.4% |
| Q1 FY2025 | $538.0K | -79.3% | $-1.6M | -302.2% |
| Q4 FY2024 | $-7.5M | -762.7% | $-24.4M | 324.4% |
| Q3 FY2024 | $1.9M | -38.4% | $-18.7M | -964.4% |
| Q2 FY2024 | $3.0M | -40.9% | $-3.0M | -99.3% |
| Q1 FY2024 | $2.6M | -55.2% | $4.2M | 163.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.6M | $3.0M | $1.9M | $-7.5M | $538000 | $2.0M | $4.0M | $10.7M |
| YoY Growth | -55.2% | -40.9% | -38.4% | -762.7% | -79.3% | -31.8% | 109.0% | 242.0% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $40.6M | $39.4M | $39.0M | $54.0M | $45.6M | $69.5M | $115.2M | $106.7M |
| Liabilities | $46.1M | $30.9M | $33.5M | $25.9M | $18.8M | $48.5M | $103.4M | $93.7M |
| Equity | $-5.5M | $8.5M | $5.5M | $28.1M | $26.8M | $21.0M | $11.7M | $13.0M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-3.0M | $-1.8M | $-1.4M | $-5.3M | $-6.7M | $-8.4M | $-5.4M | $-3.0M |